Helix BioPharma Corp. Announces Appointment of New Director and Observer to the Board of Directors
11 Mars 2014 - 10:00PM
Marketwired
Helix BioPharma Corp. Announces Appointment of New Director and
Observer to the Board of Directors
AURORA, ON--(Marketwired - Mar 11, 2014) - Helix BioPharma Corp.
(TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing
drug candidates for the prevention and treatment of cancer, today
announced the appointment of Mr. Sylwester Cacek to the board of
directors. Mr. Cacek's appointment was effective March 7,
2014.
Sylwester Cacek is currently president of Sfinks Polska SA, and
was the founder of Dominet Capital Group, which included a
nationwide retail bank Dominet Bank SA. As CEO of the group,
Mr. Cacek created a nationwide financial institution with a wide
range of products and services dedicated to individual clients and
small and medium enterprises. In 2007, Dominet SA was successfully
sold to Fortis Group. In his career, Mr. Cacek has served as a
member of supervisory boards in such companies as Dominet Bank SA,
Impel SA, OrsNet Sp. z o.o., SportLive24 SA and KS Widzew Łódź SA.
He is a shareholder of the Polish professional football club RTS
Widzew Łódź. Mr. Cacek currently holds or exercises control or
direction over, directly or indirectly, 6,934,400 common shares of
Helix.
Commenting on the appointment, Robert Verhagen, President and
CEO, said, "Mr. Cacek has many years of experience in the financial
sectors and, with his insight into business management, I look
forward to the insights he will bring to our board and to working
with him as Helix pursues its growth initiatives."
Mr. Cacek's appointment comes after the board received and
accepted Mr. Slawomir Ludwikowski's resignation from the board of
directors. A majority of the votes represented by proxy at Helix's
annual general and special meeting of shareholders held on December
18, 2013 were withheld from voting for Mr. Ludwikowski and, in
accordance with Helix's majority voting policy, Mr. Ludwikowski was
required to submit his resignation to the board of directors for
its consideration.
Helix also announced that Mr. Andreas Kandziora has been asked
to act as an Observer to the board of directors, effective March 7,
2014. Mr. Kandziora is President and CEO of Liechtenstein-based
financial advisory and business consulting firm ACM Alpha
Consulting Management Est. He has experience in the fields of
corporate development, project management and financing, marketing,
and consulting.
Mr. Verhagen commented, "Mr. Kandziora has worked with Helix
since 2007 as a vital link to our European shareholders. His status
as Observer will greatly increase our ability to communicate the
direction of the company to these shareholders effectively."
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix's
product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently
listed on the TSX and FSE under the symbol "HBP".
Forward-Looking Statements and Risks and
Uncertainties
This news release contains certain forward-looking
statements and information (collectively, "forward-looking
statements") within the meaning of applicable Canadian securities
laws, including, without limitation, those relating to the increase
in the ability of Helix to communicate effectively with its
European shareholders following Mr. Kandzioras's appointment as an
observer to the board of directors. Forward-looking
statements, which may be identified by words including, without
limitation, "will", and other similar expressions, are intended to
provide information about management's current plans and
expectations regarding the operations of Helix.
Although Helix believes that the expectations reflected in
such forward-looking statements are reasonable, such statements
involve risks and uncertainties that may cause actual results or
events to differ materially from those anticipated and no assurance
can be given that these expectations will be realized, and undue
reliance should not be placed on such statements. Risk factors that
could cause actual results or events to differ materially from the
forward-looking statements include, without limitation, those risks
and uncertainties affecting the company as more fully described in
Helix's most recent Annual Report, including under the headings
"Forward-Looking Statements" and "Risk Factors", filed with the
Canadian Securities Administrators at www.sedar.com (together, the
"Helix Risk Factors"). Certain material factors or assumptions
are applied in making the forward-looking statements, including,
without limitation, that the Helix Risk Factors will not cause
Helix's actual results or events to differ materially from the
forward-looking statements.
Forward-looking statements and information are based on the
beliefs, assumptions and expectations of Helix's management on the
date of this news release, and Helix does not assume any obligation
to update any forward-looking statement or information should those
beliefs, assumptions or expectations, or other circumstances
change, except as required by law.
Investor Relations: Helix BioPharma Corp. Tel: 905 841-2300
Email: ir@helixbiopharma.com
Helix BioPharma (TSX:HBP)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Helix BioPharma (TSX:HBP)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024